(Total Views: 944)
Posted On: 06/26/2020 11:28:28 AM
Post# of 72446
Note $1B proposed reward once Brilacidin is approved for ABSSI from page 20 of IPIX Corporate Update:
Brilacidin is 1 of only 7 “qualifying” antibiotics* in development DRIVE AB** says would merit a proposed Market Entry Reward ($1bn) due to its ability to kill “critical” or “high priority” pathogens.
See (pg.71) (pdf): http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
**Driving Reinvestment in Research and Development and Responsible
https://static1.squarespace.com/static/571535...020+fv.pdf
http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
Brilacidin is 1 of only 7 “qualifying” antibiotics* in development DRIVE AB** says would merit a proposed Market Entry Reward ($1bn) due to its ability to kill “critical” or “high priority” pathogens.
See (pg.71) (pdf): http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
**Driving Reinvestment in Research and Development and Responsible
https://static1.squarespace.com/static/571535...020+fv.pdf
http://drive-ab.eu/wp-content/uploads/2018/01...an2018.pdf
(15)
(0)
